Cargando…
Different Pathways Leading to Integrase Inhibitors Resistance
Integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL), elvitegravir, or dolutegravir (DTG), are efficient antiretroviral agents used in HIV treatment in order to inhibit retroviral integration. By contrast to RAL treatments leading to well-identified mutation resistance pathways a...
Autores principales: | Thierry, Eloïse, Deprez, Eric, Delelis, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225119/ https://www.ncbi.nlm.nih.gov/pubmed/28123383 http://dx.doi.org/10.3389/fmicb.2016.02165 |
Ejemplares similares
-
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
por: Thierry, Eloïse, et al.
Publicado: (2017) -
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
por: Richetta, Clémence, et al.
Publicado: (2022) -
Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008) -
Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration
por: Thierry, Sylvain, et al.
Publicado: (2015) -
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)